CANbridge To Develop And Commercialise ATI-1123 In China/North Asia

CANbridge Life Sciences has entered into a partnership with Azaya Therapeutics, to develop and commercialise Azaya's investigational drug, ATI-1123 (docetaxel), for the treatment of non-small cell lung cancer (NSCLC), and potentially other solid tumour cancer indications, in China and North Asia. ATI-1123, a liposomal formulation of docetaxel, has completed an FDA-approved Phase I trial in 29 patients with solid tumour cancers who had failed on other therapies. Phase II trials in the US are planned in NSCLC, gastric cancer, pancreatic cancer and soft tissue sarcoma.

Under the terms of the agreement, CANbridge obtains exclusive rights to clinically develop and commercialise ATI-1123 in China, Taiwan and South Korea. Upon ATI-1123's successful approval in these territories, CANbridge plans to manufacture the product locally and to supply the region via a technology transfer arrangement. CANbridge will be responsible for financing the development and commercialisation of ATI-1123 in the territories and will pay Azaya milestones and royalties at defined stages of the partnership. Financial terms of the deal were not disclosed.

Agreement Information:
Agreement Status: New Date Announced: 11 Sep 2013
Date Last Reported: Duration:
Est Total Value: Investment To Date:
Agreement Type: Commercialisation Development
Generic / Brand Name: ATI-1123 docetaxel
Therapeutic Area: Antineoplastic and Immunomodulating Agents
Indication: Cancer (non-small cell lung) Cancer
Techonology/Field: Drug delivery Drug development
This article is tagged to:
Sector: Pharmaceuticals & Healthcare, Medical Devices
Geography: Asia, China, North Korea, Taiwan

Enter your details to read the full article

By submitting this form you are acknowledging that you have read and understood our Privacy Policy.